Discover DURECT's Q4 2024 earnings insights, progress on larsucosterol's Phase 3 trial for alcohol-associated hepatitis, and strategies to secure funding.

Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...

Fintel reports that on March 24, 2025, Oppenheimer initiated coverage of Quince Therapeutics (NasdaqGS:QNCX) with a ...

Oppenheimer downgraded Arvinas (ARVN) to Perform from Outperform and removed the firm’s price target on the shares after the company announced ...

Oppenheimer analyst Matthew Biegler says Olema Oncology (OLMA) published a revised corporate deck today which included an update from the palazestrant plus ribociclib combination trial.

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) had its price objective cut by BTIG Research from $5.00 to $4.00 in a ...

Suraj, Senior Medical Device Analyst, Oppenheimer: Waleed, switching gears, clinical trials and the next generation products and indications is something that also dominates client conversations.

Suraj, Senior Medical Device Analyst, Oppenheimer: Waleed, switching gears, clinical trials and the next generation products and indications is something that also dominates client conversations.

Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) was upgraded by equities research analysts at Oppenheimer from a “market ...

Darden Restaurants reported third-quarter earnings below expectations, with sales of $3.158 billion missing the consensus ...